(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
LATEST POSTS
- 1
South Africa pushes for $200B investment - 2Monetary Versatility: Get ready for Life's Unforeseen Difficulties
- 34 Sound blocking Earphones for Prevalent Sound and Solace
- 4Role reversal: Ukraine moves training home and exports the lessons abroad
- 5The race to mine the moon is on – and it urgently needs some clear international rules
- Everyone knows F1 is for the girls. I wandered into the Las Vegas desert to find out why.
- Kids get diseases like lupus, too. As researchers hunt better treatments, this camp brings joy
- A 3-limbed Kemp's ridley sea turtle is now being tracked at sea by satellite
- Figure out How to Keep up with Oral Wellbeing During Pregnancy
- UN mission says no evidence Hezbollah rearming in southern Lebanon
- Artemis 2 astronauts are about to see one of the rarest skywatching sights of all — a solar eclipse from beyond the moon
- 23 Most Amusing Messages At any point Sent Among Kids and Their Folks
- Figuring out Significant Regulations and Guidelines for Organizations
- What's your biological age? Experts explain the benefits and risks of at-home tests
